Evaluating Anti-Tobacco Message Effectiveness Among Lesbian, Gay, Bisexual, and Transgender Young Adults

The Effect of Nicotine and Tobacco Message Framing on Use Among Diverse Groups of Young Adults

This trial refines and evaluates anti-tobacco messages among lesbian, gay, bisexual, and transgender (LGBT) young adults at risk for the use of more than one tobacco product (polytobacco use). Polytobacco use is associated with nicotine dependence and tobacco use into adulthood, and is disproportionately high among LGBT young adults. This trial seeks to determine effective communication of polytobacco use risk to at-risk LGBT young adults.

Study Overview

• Status: Completed
• Conditions: Tobacco-Related Carcinoma
• Intervention / Treatment: Other: Health communications

Detailed Description

PRIMARY OBJECTIVES:

I. Identify absolute and relative risk anti-tobacco messages that effectively communicate polytobacco risks to lesbian, gay, bisexual, transgender (LGBT) young adults.

Participants view anti-tobacco messages and rate them for perceived effectiveness and reactance.

• Study Type: Interventional
• Enrollment (Actual): 2849
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Ohio
    • Columbus, Ohio, United States, 43210
      • Ohio State University Comprehensive Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 35 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Young adults (age 18-35 years)
• Live in the United States

At least 50% of the sample also:

• Are susceptible to multiple nicotine and tobacco product use (i.e., have used combustible tobacco or e-cigarettes at least once)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Factorial Assignment
• Masking: Single

Number of Arms

7

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: AR-Quit; Participants view messages with absolute risk and quit statements	Other: Health communications; Participants are assigned to view health communications with risk and efficacy statements.
Experimental: AR-Switch; Participants view messages with absolute risk and switch statements	Other: Health communications; Participants are assigned to view health communications with risk and efficacy statements.
Experimental: AR-Combination; Participants view messages with absolute risk and combination quit+switch statements	Other: Health communications; Participants are assigned to view health communications with risk and efficacy statements.
Experimental: RR-Quit; Participants view messages with comparative risk and quit statements	Other: Health communications; Participants are assigned to view health communications with risk and efficacy statements.
Experimental: RR-Switch; Participants view messages with comparative risk and switch statements	Other: Health communications; Participants are assigned to view health communications with risk and efficacy statements.
Experimental: RR-Combination; Participants view messages with comparative risk and combination quit+switch statements	Other: Health communications; Participants are assigned to view health communications with risk and efficacy statements.
Other: Control; Participants view FDA regulatory messages	Other: Health communications; Participants are assigned to view health communications with risk and efficacy statements.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Message Perceived Effectiveness - Persuasive Potential.	6 items measured on 5-point scale, 1 = Not at all and 5 = Very much; These messages were worth remembering.; These messages grabbed my attention.; These messages are powerful.; These messages are convincing.; These messages are meaningful.; These messages are informative. Responses were summed and averaged to create a scale for intention to quit (range from 1 - 5). Higher scores indicate a higher persuasive potential of the message.	Immediately post-exposure to intervention, up to 1 hour
Perceived Effectiveness - Perceived Behavioral Impact	Six items were analyzed separately, each scored on 5-point Likert scale (1=Strongly Disagree, 5=Strongly Agree) These messages will motivate CIGARETTE SMOKERS to switch to vaping. These messages will motivate people to quit ALL smoking and vaping. These messages will motivate NON-USERS to start vaping. These messages will motivate NON-USERS to start smoking cigarettes. These messages will motivate CIGARETTE SMOKERS to quit. These messages will motivate VAPERS to quit.	Immediately post-exposure to intervention, up to 1 hour
Risk Perceptions: Absolute/Relative Risks of Cigarette vs. E-cigarette Use	On a scale from 0-10, where 0 = not at all harmful and 10 = extremely harmful now harmful are ... to your health?; combustible cigarettes; nicotine vapes On a scale from 0-10, where 0 = much less harmful and 10 = much more harmful... • compared to combustible cigarettes, how harmful are nicotine vapes to your health?	Immediately post-exposure to intervention, up to 1 hour
Behavioral Intentions to Use Tobacco	8-items made up two 4-pt scales (1 = definitely will not and 4 = definitely will). Items for each scale were summed and averaged. Higher scores indicate higher likelihood of avoiding cigarettes/nicotine vapes. How likely it is that in the next 3 months, you will refrain from...; smoking cigarettes completely and permanently?; smoking cigarettes when you get lonely?; smoking cigarettes when you are with your friends who use them?; smoking cigarettes when someone hands you a cigarette? How likely it is that in the next 3 months, you will refrain from...; vaping nicotine completely and permanently?; vaping nicotine when you get lonely?; vaping nicotine when you are with your friends who use them?; vaping nicotine when someone hands you a vape?	Immediately post-exposure to intervention, up to 1 hour

Collaborators and Investigators

• Sponsor: Ohio State University Comprehensive Cancer Center
• Collaborators: National Cancer Institute (NCI)
• Investigators: Principal Investigator: Joanne G Patterson, PhD MPH MSW, Ohio State University Comprehensive Cancer Center

Publications and helpful links

Helpful Links

• The Jamesline

Study record dates

Study Major Dates

• Study Start (Actual): April 14, 2021
• Primary Completion (Actual): November 14, 2022
• Study Completion (Actual): November 14, 2022

Study Registration Dates

• First Submitted: May 18, 2022
• First Submitted That Met QC Criteria: May 23, 2022
• First Posted (Actual): May 26, 2022

Study Record Updates

• Last Update Posted (Actual): December 26, 2023
• Last Update Submitted That Met QC Criteria: December 5, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Other Study ID Numbers: OSU-20427; NCI-2022-02543 (Registry Identifier: CTRP (Clinical Trial Reporting Program)); K99CA260718 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No